



Chad King, PhD
Executive Director, Research and Site Head
Amgen British Columbia

Chad is the Executive Director, Research and Site Head of Amgen British Columbia. The Biologics Discovery team that Chad leads is focussed on the discovery of novel antibodies and large molecules in support of Amgen's Therapeutic molecule pipeline. In addition, this team generates non-therapeutic antibody tools to support a wide range of drug discovery activities at various stages of development and commercialization; Discovery research, Safety

Sciences, PKDM and Biomarker Discovery. Chad is passionate about new technology development to support novel Therapeutic Discovery platforms. He is a named co-inventor on a large portfolio of patents and applications representing 20+ different large molecule therapeutics including Repatha (evolocumab) and Aimovig (erenumab).